Zevra Therapeutics, Inc. (ZVRA)

Zevra Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	54.44	33.79	43.05	65.47	112.35	4.21
Short-Term Investments	145.07	35.71	24.69	17.38	-	-
Cash & Short-Term Investments	199.51	69.5	67.74	82.85	112.35	4.21
Cash Growth	123.22%	2.60%	-18.24%	-26.26%	2566.65%	30.96%
Accounts Receivable	9.97	10.18	16.12	7.19	1.42	2.44
Other Receivables	6.87	0.33	1.26	1.11	0.11	0.14
Receivables	16.84	10.51	17.38	8.3	1.53	2.58
Inventory	1.37	1.97	-	-	-	-
Prepaid Expenses	7.4	4.05	1.82	1.69	0.89	0.66
Restricted Cash	-	-	-	-	-	0.11
Other Current Assets	-	-	-	-	0.29	0.83
Total Current Assets	225.12	86.03	86.94	92.83	115.06	8.38
Property, Plant & Equipment	1.83	1.01	1.53	1.78	2.03	2.39
Long-Term Investments	30.87	6.01	-	20	15.42	-
Goodwill	4.7	4.7	4.7	-	-	-
Other Intangible Assets	6.74	68.99	69.23	-	-	-
Long-Term Accounts Receivable	-	-	-	-	-	0.4
Other Long-Term Assets	0.87	11.38	9.94	0.72	0.44	0.04
Total Assets	270.12	178.13	172.33	115.34	132.94	11.21
Accounts Payable	11.07	13.08	13.99	3.61	0.52	1.17
Accrued Expenses	5.61	17.37	18.97	7.21	2.52	5.47
Short-Term Debt	-	-	37.7	-	-	-
Current Portion of Long-Term Debt	-	-	-	-	-	0.39
Current Portion of Leases	0.44	0.42	0.54	0.49	0.37	0.5
Other Current Liabilities	8.99	3.2	2.52	0.71	0.82	-
Total Current Liabilities	26.11	34.07	73.72	12.02	4.23	7.54
Long-Term Debt	61.31	59.5	5.07	12.8	-	68.05
Long-Term Leases	0.97	0.37	0.46	0.84	1.24	1.61
Other Long-Term Liabilities	48.56	44.52	31.22	14.55	0.36	0.43
Total Liabilities	136.95	138.46	110.46	40.22	5.82	77.62
Common Stock	0.01	0.01	0	0	0	-
Additional Paid-In Capital	580.78	555.3	472.66	436.27	396.96	192.06
Retained Earnings	-434.23	-505.29	-399.78	-353.73	-267.03	-258.47
Treasury Stock	-10.98	-10.98	-10.98	-7.54	-2.81	-
Comprehensive Income & Other	-2.42	0.63	-0.04	0.11	-	-
Total Common Equity	133.17	39.67	61.86	75.12	127.12	-66.41
Shareholders' Equity	133.17	39.67	61.86	75.12	127.12	-66.41
Total Liabilities & Equity	270.12	178.13	172.33	115.34	132.94	11.21
Total Debt	62.72	60.3	43.77	14.13	1.61	70.55
Net Cash (Debt)	136.79	9.2	23.97	68.72	110.74	-66.33
Net Cash Growth	364.50%	-61.62%	-65.11%	-37.95%	-	-
Net Cash Per Share	2.44	0.20	0.68	1.99	3.72	-16.66
Filing Date Shares Outstanding	56.3	54.12	41.85	34.54	34.42	28.38
Total Common Shares Outstanding	56.22	53.67	41.53	34.54	35.01	4.54
Working Capital	199	51.96	13.22	80.81	110.83	0.85
Book Value Per Share	2.37	0.74	1.49	2.17	3.63	-14.64
Tangible Book Value	121.73	-34.03	-12.06	75.12	127.12	-66.41
Tangible Book Value Per Share	2.17	-0.63	-0.29	2.17	3.63	-14.64
Machinery	-	1.36	1.51	1.28	1.05	1.01
Leasehold Improvements	-	0.71	0.71	0.71	0.72	0.72

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q